The value of serum CA153 and miR-10b in the diagnosis of early breast cancer
CHENG Wen1 PAN Guangrui2 ZENG An’gui1 WANG Yi1 LI Pan1
1.Thyroid and Breast Surgery Department, Affiliated Hospital of Panzhihua University Panzhihua Integrated Hospital of Traditional Chinese and Western Medicine, Sichuan Province, Panzhihua 617067, China;
2.Breast Surgery Department, Kangjiancheng District of Affiliated Hospital of Southwest Medical University, Sichuan Province, Luzhou 646000, China
Abstract：Objective To investigate the value of serum carbohydrate antigen 153 (CA153) and microRNA-10b (miR-10b) in the diagnosis of early breast cancer. Methods Seventy-nine patients with early breast cancer diagnosed and treated in Affiliated Hospital of Panzhihua University (“our hospital” for short) from February 2018 to February 2020 were selected as breast cancer group, and 42 healthy subjects underwent physical examination in our hospital during the same period were selected as control group. Serum CA153 level was detected by enzyme-linked immunosorbent assay, serum miR-10b level was detected by real-time fluorescent quantitative PCR, and the diagnostic value of serum CA153 and miR-10b in early breast cancer was analyzed by receiver operating characteristic curve. Results The serum levels of CA153 and miR-10b in breast cancer group were significantly higher than those in control group (P < 0.05). There were significant differences in serum CA153 levels of breast cancer patients with different estrogen receptor (ER), histological differentiation and TNM stages (P < 0.05). The expression levels of serum miR-10b of breast cancer patients with different HER2 and TNM stages were significantly different (P < 0.05). The area under the curve, sensitivity and specificity of CA153 combined with miR-10b in the diagnosis of early breast cancer were higher than those of CA153 and miR-10b alone. Conclusion Serum levels of CA153 and miR-10b are significantly increased in patients with early breast cancer, ER expression, degree of differentiation and TNM stage are correlated with serum CA153 level, and HER2 expression and TNM stage are correlated with serum miR-10b level. The combined detection of the two is of certain clinical value in the diagnosis of early breast cancer.
程文1 潘广锐2 曾安贵1 王毅1 李攀1. 血清CA153、miR-10b在早期乳腺癌诊断中的价值[J]. 中国医药导报, 2021, 18(5): 101-104,116.
CHENG Wen1 PAN Guangrui2 ZENG An’gui1 WANG Yi1 LI Pan1. The value of serum CA153 and miR-10b in the diagnosis of early breast cancer. 中国医药导报, 2021, 18(5): 101-104,116.
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] 孙永辉，陶维阳.乳腺癌前哨淋巴结活检研究进展[J].现代肿瘤医学，2017，25（4）：634-637.
[3] Jafari SH，Saadatpour Z，Salmaninejad A，et al. Breast cancer diagnosis：imaging techniques and biochemical markers [J]. J Cell Physiol，2018，233（7）：5200-5213.
[4] 陈亚龙，赵绒.CA125、CA153、CEA水平在卵巢癌诊断中的价值[J].实用癌症杂志，2019，34（4）：173-175.
[5] 申燕军，陈京龙，李文东，等.原发性肝癌患者术前CEA和CA153与临床病理特征和预后的关系[J].医学综述，2018，24（23）：188-192.
[6] Lu TX，Rothenberg ME. MicroRNA [J]. J Allergy Clin Immunol，2018，141（4）：1202-1207.
[7] Ganju A，Khan S，Hafeez BB，et al. miRNA nanotherapeutics for cancer [J]. Drug Discov Today，2017，22（2）：424-432.
[8] 耿帅，郭宏举，史宁，等.微RNA对肿瘤调控机制的研究进展[J].中国新药与临床杂志，2020，39（4）：193-197.
[9] Sheedy P，Medarova Z. The fundamental role of miR-10b in metastatic cancer [J]. Am J Cancer Res，2018，8（9）：1674-1688.
[10] 冯磊，常春红，管晓卿，等.宫颈癌患者血浆miRNA-10b的表达及其临床意义[J].现代检验医学杂志，2018， 33（1）：52-55.
[11] 郑唯强.乳腺癌分子病理诊断的机遇与挑战[J].临床与实验病理学杂志，2017，33（5）：473-476.
[12] 师金，梁迪，李道娟，等.全球女性乳腺癌流行情况研究[J].中国肿瘤，2017，26（9）：683-690.
[13] 李稳，陈玉娟，汪静.三阴性乳腺癌的临床病理特征及治疗进展[J].华西医学，2017，32（2）：267-270.
[14] 彭晓燕.转移性三阴性乳腺癌的治疗进展[J].中国医药科学，2019，9（16）：56-58.
[15] 史文婷，肖秋梅，张相机，等.乳腺癌新辅助化疗疗效的影响因素研究[J].中国医药科学，2020，10（16）:130-133.
[16] Sun YS，Zhao Z，Yang ZN，et al. Risk factors and preventions of breast cancer [J]. Int J Biol Sci，2017，13（11）：1387-1397.
[17] 易帆，曾召琼，邓长娟，等.MicroRNA在乳腺癌研究中的新进展[J].中华检验医学杂志，2019，42（10）：884-889.
[18] Liu B，Pan S，Xiao Y，et al. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway [J]. J Exp Clin Cancer Res，2018，37（1）：316.
[19] Sharma VR，Gupta GK，Sharma AK，et al. PI3K/Akt/mTOR intracellular pathway and breast cancer：factors，mechanism and regulation [J]. Curr Pharm Des，2017，23（11）：1633-1638.
[20] Shah M，Cardenas R，Wang B，et al. HOXC8 regulates self-renewal，differentiation and transformation of breast cancer stem cells [J]. Mol Cancer，2017，16（1）：38.
[21] 黄增光，荣震，石玮，等.ER、PR、CA-153、Ki-67的表达与乳腺癌临床病理特征及预后的相关性研究[J].现代生物医学进展，2018，18（10）：1948-1951.
[22] Tonsing-Carter E，Hernandez KM，Kim CR，et al. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association [J]. Breast Cancer Res，2019，21（1）：82.
[23] 唐静，石中全，胡玲，等.过表达miR-10b促进肺癌细胞系A549增殖[J].基础医学与临床，2017，37（8）：1108-1112.
[24] 曹晓智，高恬媛，汪俊茹，等.NF-Y调控KLF4转录对乳腺癌细胞增殖、迁移的影响[J].山东医药，2019，59（31）：9-13.
[25] 左华，陈晓军，周冬，等.血清miR-574-5p和miR-10b在乳腺癌中的表达及临床意义[J].河北医药，2019，41（8）：1136-1139.
[26] 茹琴，李超英.miR-10b对脑胶质瘤恶性生物学行为的调控及其机制[J].中国肿瘤生物治疗杂志，2018，25（4）：376-381.
[27] Wuerstlein R，Harbeck N. Neoadjuvant therapy for HER2-positive breast cancer [J]. Rev Recent Clin Trials，2017， 12（2）：81-92.
2021, Vol. 18 
京公网安备 11010502046598号